Exalenz Bioscience (Israel) Financial Diagnostics

EXEN -- Israel Stock  

ILS 1,014  1.00  0.1%

Exalenz Bioscience Ltd diagnostics interface makes it easy to digest most current publicly released information about Exalenz Bioscience as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Exalenz Bioscience price relationship with some important fundamental indicators such as market cap and management efficiency.

Exalenz Bioscience Note

The company recorded loss per share of 0.17. Exalenz Bioscience Ltd had not issued any dividends in recent years. This company had 1:100 split on 2014-12-21. Exalenz Bioscience Ltd. develops and markets advanced tools for the diagnosing and managing liver and gastroenterology disorders in Israel. Exalenz Bioscience Ltd. is based in Modiin-Maccabim-Reut, Israel. Exalenz Bioscience is traded on Tel Aviv Stock Exchange in Israel. To learn more about EXALENZ BIOSCIENC call the company at 972 8 973 7500 or check out http://www.exalenz.com.

Exalenz Bioscience Alerts

Exalenz Bioscience is not yet fully synchronised with the market data
Exalenz Bioscience generates negative expected return over the last 30 days
The company reported revenue of 11.03 M. Net Loss for the year was (4.43 M) with profit before overhead, payroll, taxes, and interest of 3.58 M.
EXALENZ BIOSCIENC has accumulated about 2.5 M in cash with (4.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09.
Latest headline from dailyindustryreports.com: Helicobacter Pylori Non-invasive Testing Market is Estimated to Reach a Value of US 731.9 Mn by 2026

Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 343.83 M.

Profitablity

The company has Profit Margin (PM) of (40.19) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (39.94) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.4.

Management Efficiency

Exalenz Bioscience Ltd has return on total asset (ROA) of (29.93) % which means that it has lost $29.93 on every $100 spent on asset. This is way below average.

Exalenz Bioscience Technical and Predictive Indicators

Did you try this?

Run Portfolio Reporting Now

   

Portfolio Reporting

Create custom reports across your portfolios and generate quick suggestion pitch
All  Next Launch Portfolio Reporting

Also Currentnly Active

Purchased over 100 shares of
a day ago
Traded for 41.84
Purchased over 100 shares of
a day ago
Traded for 28.79
Purchased over 100 shares of
a day ago
Traded for 108.66
Additionally see Investing Opportunities. Please also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Search macroaxis.com